AI Article Synopsis
- Obesity is linked to higher risks of cardiovascular diseases (CVD) and type 2 diabetes (T2D), prompting a study to evaluate body mass index (BMI) and waist circumference (WC) as predictive measures among Jordanian adults.
- The research involved 6000 participants across Jordan, revealing that while BMI is associated with increased T2D risk, waist circumference is a better predictor for CVD risk.
- Findings suggest that public health interventions in Jordan and similar regions should focus on waist circumference to effectively reduce CVD and T2D risks.
Article Abstract
Obesity is strongly associated with cardiovascular diseases (CVD) and type 2 diabetes (T2D). This study aimed to use obesity measures, body mass index (BMI) and waist circumference (WC) to predict the CVD and T2D risk and to determine the best predictor of these diseases among Jordanian adults. A cross-sectional study was conducted at the governmental and military hospitals across Jordan. The study participants were healthy or previously diagnosed with CVD or T2D. The continuous variables were compared using ANOVA, and the categorical variables were compared using the X2 test. The multivariate logistic regression was used to predict CVD and T2D risk through their association with BMI and WC. The final sample consisted of 6000 Jordanian adults with a mean age of 41.5 ± 14.7 years, 73.6% females. The BMI (OR = 1.7, CI: 1.30-2.30, < 0.001) was associated with a higher risk of T2D compared to WC (OR = 1.3, CI: 1.04-1.52, = 0.016). However, our results showed that BMI was not associated with CVD risk, while the WC was significantly and positively associated with CVD risk (OR = 1.9, CI: 1.47-2.47, < 0.001). In conclusion, an elevated BMI predicts a higher risk of T2D, while WC is more efficient in predicting CVD risk. Our results can be used to construct a population-specific intervention to reduce the risk of CVD and T2D among adults in Jordan and other countries with similar backgrounds.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618033 | PMC |
| http://dx.doi.org/10.3390/ijerph182212187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The added value of ECG abnormalities in predicting incident cardiovascular disease risk for people with type 2 diabetes: The Hoorn Diabetes Care System cohort.
Eur J Prev Cardiol
January 2025
Amsterdam UMC location Vrije Universiteit Amsterdam, Department of General Practice Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.
Aims: To investigate if adding ECG abnormalities as a predictor improves the performance of incident CVD-risk prediction models for people with type 2 diabetes (T2D).
Methods: We evaluated the four major prediction models that are recommended by the guidelines of the American College of Cardiology/American Heart Association and European Society of Cardiology, in 11,224 people with T2D without CVD (coronary heart disease, heart failure, stroke, thrombosis) from the Hoorn Diabetes Care System cohort (1998-2018). Baseline measurements included CVD-risk factors and ECG recordings coded according to the Minnesota Classification as no, minor or major abnormalities.
Identification of Interactive Genetic Loci Linked to Insulin Resistance in Metabolic Syndrome-An Update.
Medicina (Kaunas)
January 2025
Asir Health Cluster, Tarj General Hospital, Bisha 67721, Saudi Arabia.
Metabolic syndrome is a metabolic disorder characterized by hypertension, dyslipidemia, impaired glucose tolerance, and abdominal obesity. Impaired insulin action or insulin resistance initiates metabolic syndrome. The prevalence of insulin resistance is increasing all over the world.
View Article and Find Full Text PDFLifestyle scores and their potential to estimate the risk of multiple non-communicable disease-related endpoints: a systematic review.
BMC Public Health
January 2025
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Background: Lifestyle scores have emerged as a practical tool to assess the risk of major non-communicable diseases (NCDs). However, most of them are primarily developed for single NCDs. Given the common risk factors for some of the major NCDs, we conducted a systematic review to evaluate the potential of existing lifestyle scores in predicting the risk of multiple NCD-related endpoints.
View Article and Find Full Text PDFMetabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System.
Trends Cardiovasc Med
January 2025
Department of Cardiology, Euroclinic Hospital, Athens, Greece; First Department of Cardiology, Athens University School of Medicine, Athens, Greece. Electronic address:
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty-liver disease, is an important and rising health issue with a link with atherosclerotic cardiovascular (CV) disease (CVD), affecting ∼25-30% of the adults in the general population; in patients with diabetes, its prevalence culminates to ∼70%; its evolutive form, nonalcoholic steatohepatitis, is estimated to be the main cause of liver transplantation in the future. MASLD is a multisystem disease that affects, besides the liver, extra-hepatic organs and regulatory pathways; it raises the risk of type 2 diabetes mellitus (T2D), CVD, and chronic kidney disease; the disease may also progress to hepatocellular carcinoma. Its diagnosis requires hepatic steatosis and at least one cardiometabolic risk factor and the exclusion of both significant alcohol consumption and other competing causes of chronic liver disease.
View Article and Find Full Text PDFComparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.
JAMA Intern Med
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.
Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!